| Item Type | Name |
|
Concept
|
Vaccines, Attenuated
|
|
Concept
|
Cancer Vaccines
|
|
Concept
|
Vaccines, Subunit
|
|
Academic Article
|
Mechanisms of T-cell inhibition: implications for cancer immunotherapy.
|
|
Academic Article
|
Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
|
|
Academic Article
|
AE37: a novel T-cell-eliciting vaccine for breast cancer.
|
|
Academic Article
|
Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.
|
|
Academic Article
|
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
|
|
Academic Article
|
Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
|
|
Academic Article
|
Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
|
|
Academic Article
|
The GP2 peptide: a HER2/neu-based breast cancer vaccine.
|
|
Academic Article
|
Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides.
|
|
Academic Article
|
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
|
|
Academic Article
|
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
|
|
Academic Article
|
Breast cancer vaccines: promise for the future or pipe dream?
|
|
Academic Article
|
Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
|
|
Academic Article
|
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
|
|
Academic Article
|
CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).
|
|
Academic Article
|
The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
|
|
Academic Article
|
Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.
|
|
Academic Article
|
Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.
|
|
Academic Article
|
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
|
|
Academic Article
|
Cancer vaccines: should we be targeting patients with less aggressive disease?
|
|
Academic Article
|
The E75 HER2/neu peptide vaccine.
|
|
Academic Article
|
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
|
|
Academic Article
|
Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?
|
|
Academic Article
|
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax?) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.
|
|
Academic Article
|
Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.
|
|
Academic Article
|
Cancer vaccines in the new era of cancer immunotherapy.
|
|
Academic Article
|
Adjuvant HER2/neu peptide cancer vaccines in breast cancer.
|
|
Academic Article
|
Cancer vaccines in the new era of cancer immunotherapy
|
|
Academic Article
|
HER-2/neu Peptide Breast Cancer Vaccines
|
|
Academic Article
|
Breast Cancer Vaccines
|
|
Academic Article
|
Injecting hope-A review of breast cancer vaccines
|
|
Academic Article
|
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
|
|
Academic Article
|
Injecting Hope--A Review of Breast Cancer Vaccines.
|
|
Academic Article
|
The development and use of the E75 (HER2 369-377) peptide vaccine.
|
|
Academic Article
|
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
|
|
Academic Article
|
Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+?T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.
|
|
Academic Article
|
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
|
|
Academic Article
|
Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
|
|
Academic Article
|
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
|
|
Academic Article
|
Investigation of parameters that determine Nano-DC vaccine transport.
|
|
Academic Article
|
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.
|
|
Academic Article
|
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
|
|
Academic Article
|
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
|
|
Academic Article
|
Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine.
|
|
Academic Article
|
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ.
|